5:57 PM
 | 
Nov 28, 2012
 |  BC Extra  |  Company News

EMA accepts vintafolide, etarfolatide MAAs

Endocyte Inc. (NASDAQ:ECYT) and partner Merck & Co. Inc. (NYSE:MRK) said EMA accepted for review MAAs for conditional approval of vintafolide and companion diagnostic etarfolatide to treat folate receptor-positive...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >